GSKGLAXF -5.57%75 Market Cap is $104,616 Mil as of Jun. 26, 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.80 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,023 Drug Manufacturers companies, GSK ranks better than 98.73% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). GSK's share price for the quarter that ended in Mar. 2026 was $27.245. GSK's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 4,020 Mil. Therefore, GSK's market cap for the quarter that ended in Mar. 2026 was $109,532 Mil.
GSK's quarterly market cap
increased
from Sep. 2025 ($83,989 Mil) to Dec. 2025 ($98,709 Mil) and
increased
from Dec. 2025 ($98,709 Mil) to Mar. 2026 ($109,532 Mil).
GSK's annual market cap
declined
from Dec. 2023 ($74,818 Mil) to Dec. 2024 ($68,660 Mil) but then
increased
from Dec. 2024 ($68,660 Mil) to Dec. 2025 ($98,709 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GSK's Enterprise Value for Today is $117,418 Mil.
GSK (OTCPK:GLAXF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GSK Market Cap Related Terms
GSK Market Cap Historical Data
* Premium members only.
The historical data trend for GSK's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GSK's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Market Cap distribution charts can be found below:
* The bar in red indicates where GSK's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
GSK's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a Market Cap of $104,616 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GSK and its competitors. According to the industry distribution chart, GSK ranks #13 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is GSK's Market Cap too high?
GSK's current Market Cap is $104,616 Mil. The Drug Manufacturers industry median Market Cap is 206.50. GSK's value of $104,616 Mil is 50562% above this industry median. Based on the distribution chart, GSK ranks #13 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #13 out of 1023 companies for Market Cap. This places GSK in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.50. GSK's value of $104,616 Mil is 50562% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Market Cap of $104,616 Mil is 50562% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Market Cap is $104,616 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.80, compared to a current price of $25.33 — trading 16.2% above its estimated fair value. The current Market Cap is $104,616 Mil and 50562% above the Drug Manufacturers industry median of 206.50. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For GSK (GLAXF), the current Market Cap is $104,616 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.33 is trading 16.2% above its estimated GF Value™ of $21.80.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Market Cap: $104,616 Mil
GF Value™: $21.80 vs. price of $25.33 (16.2% above fair value)
Industry Position: 50562% above the Drug Manufacturers median (#13 of 1023)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score
Get the complete analysis for GLAXF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
